Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies. These diseases affect millions of people around the world. We work in partnership with global companies, government agencies, leading academic institutions and non-governmental organisations with the goal of making a material and lasting positive impact on global health.
Our ImplaVax®-enabled vaccination products leverage our innovative rapidly dispersing solid-dose formulation and needle-free delivery technologies and are applicable across all vaccine formats.
ImplaVax® products are designed to enhance the immune response and offer significant benefits for patients, care givers, healthcare professionals and payers through enhanced effectiveness, safety, ease of use, assured dose delivery, reliability and thermal stability. There is strong subject preference for ImplaVax® delivered products over administration using needle and syringe. They can be administered with minimal training and are also rapidly deployable while eliminating the need for cold-chain storage.
Enesi’s experienced leadership team has a proven track record in the successful development and commercialisation of innovative products delivering high value outcomes for all stakeholders. Follow Enesi on Twitter at www.twitter.com/enesi_pharma